Trial start Phase 2: Study to Evaluate the Efficacy, Safety, and Tolerability of PIPE 791 in Subjects With Idiopathic Pulmonary Fibrosis source ↗
Raise Follow-on offering: $90M (total, as published), announced Dec 11, 2025. Source: SEC filing. source ↗
Trial start Phase 1: Study of PIPE-791 for Subjects With Chronic Osteoarthritis Pain or Chronic Low Back Pain source ↗
Trial start Phase 1: PET Study of PIPE-791 in Healthy Volunteers and Volunteers With PrMS and IPF source ↗
Trial start Phase 1: Study Evaluating Safety and Tolerability of Escalating Single and Multiple Doses of PIPE-791 and Food Effect in Healthy Volunteers source ↗
Trial start Phase 1: PET Study to Determine the Relationship Between Plasma Concentrations and Muscarinic Type 1 Receptor (M1AChR) Occupancy of PIPE-307 in Healthy Volunteers source ↗
Trial start I: Phase I Study Evaluating Safety and Tolerability of Escalating Single and Multiple Doses of of PIPE-307 and Food Effect in Healthy Volunteers source ↗
Trial start I: Phase I/IIa Study Evaluating Safety and Efficacy of an Intratympanic Dose of PIPE-505 in Subjects With Hearing Loss source ↗
Upcoming milestones
2028-05 (ESTIMATED) · Phase 2 · Study to Evaluate the Efficacy, Safety, and Tolerability of PIPE 791 in Subjects With Idiopathic Pulmonary Fibrosis · NCT07284459
Estimated primary completion per ClinicalTrials.gov. Dates move.
Funding
Raised: $90.0M. Last 2 years.
Follow-on offering: $90M (total, as published), announced Dec 11, 2025. Source: SEC filing. source ↗
PET Study to Determine the Relationship Between Plasma Concentrations and Muscarinic Type 1 Receptor (M1AChR) Occupancy of PIPE-307 in Healthy Volunteers
Level (Entry/Mid/Senior/Executive) is estimated from the job title and required years of experience. Descriptions are short excerpts (about the first 60 words) of the posting plus skills picked out of it; use Read full posting for the complete text.
